Literature DB >> 10037724

Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells.

C B Liu1, T Itoh, K Arai, S Watanabe.   

Abstract

The Janus tyrosine kinase 2 (JAK2) plays an essential role of cytokine receptor signaling, including that of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. We reported earlier that the activation of JAK2 is essential for all the examined signals induced by human GM-CSF through the box1 region of betac, such as promotion of cell survival and proliferation. To elucidate the role of JAK2 in cell survival and proliferation, we generated an artificial activation system by constructing a chimeric molecule (beta/JAK2) consisting of betac extracellular and transmembrane regions fused with JAK2, and we analyzed various signaling events in interleukin-3-dependent mouse pro-B cell, BA/F3. The beta/JAK2 was constitutively phosphorylated in the absence of human GM-CSF and murine interleukin-3, and this led to proliferation and cell survival. Western blot analysis showed that STAT5, Shc, and SHP-2 were not phosphorylated in the cells, and the consistent activation of beta-casein and c-fos promoters was not enhanced. In contrast, c-myc transcription was constitutively activated. We propose that the activation of beta/JAK2 suffices for survival and proliferation and that the activation of STAT5 and mitogen-activated protein kinase cascade is not required for these activities in BA/F3 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037724     DOI: 10.1074/jbc.274.10.6342

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit.

Authors:  Michelle Perugini; Anna L Brown; Diana G Salerno; Grant W Booker; Cvetan Stojkoski; Timothy R Hercus; Angel F Lopez; Margaret L Hibbs; Thomas J Gonda; Richard J D'Andrea
Journal:  Blood       Date:  2010-02-19       Impact factor: 22.113

2.  Two distinct signaling pathways downstream of Janus kinase 2 play redundant roles for antiapoptotic activity of granulocyte-macrophage colony-stimulating factor.

Authors:  R Liu; T Itoh; K I Arai; S Watanabe
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

Review 3.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

4.  Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Authors:  N Gefen; V Binder; M Zaliova; Y Linka; M Morrow; A Novosel; L Edry; L Hertzberg; N Shomron; O Williams; J Trka; A Borkhardt; S Izraeli
Journal:  Leukemia       Date:  2009-11-05       Impact factor: 11.528

5.  Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function.

Authors:  Sophia Pinz; Samy Unser; Dominik Buob; Philipp Fischer; Belinda Jobst; Anne Rascle
Journal:  Nucleic Acids Res       Date:  2015-03-13       Impact factor: 16.971

6.  The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.

Authors:  Sophia Pinz; Samy Unser; Susanne Brueggemann; Elisabeth Besl; Nafisah Al-Rifai; Hermina Petkes; Sabine Amslinger; Anne Rascle
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

7.  The natural chemopreventive agent sulforaphane inhibits STAT5 activity.

Authors:  Sophia Pinz; Samy Unser; Anne Rascle
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

8.  Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer.

Authors:  Sophia Pinz; Samy Unser; Anne Rascle
Journal:  BMC Mol Biol       Date:  2016-04-14       Impact factor: 2.946

9.  Functional characterization of NPM1-TYK2 fusion oncogene.

Authors:  Sudhakiranmayi Kuravi; Riley W Baker; Muhammad Umair Mushtaq; Irfan Saadi; Tara L Lin; Carolyn J Vivian; Anusha Valluripalli; Sunil Abhyankar; Siddhartha Ganguly; Wei Cui; Kojo S J Elenitoba-Johnson; Danny R Welch; Roy A Jensen; Yogen Saunthararajah; Joseph P McGuirk; Ramesh Balusu
Journal:  NPJ Precis Oncol       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.